148
Participants
Start Date
September 30, 2012
Primary Completion Date
June 1, 2018
Study Completion Date
December 31, 2020
Gemcitabine
Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
pazopanib
Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
University of Virginia, Charlottesville
Virginia Commonwealth University, Richmond
Duke University, Durham
University of Wisconsin-Madison, Madison
Stephenson Cancer Center University of Oklahoma Health Sciences Center, Oklahoma City
MD Anderson, Houston
Maine Medical Center (MMP Women's Health), Scarborough
Collaborators (1)
Novartis
INDUSTRY
Linda R Duska
OTHER